Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
People with hypertension (high blood pressure in the arteries that supply the lungs, also known as PAH) have up to a two-fold reduction in pulmonary vascular resistance (PVR) when taking PAH.
Read Full NewsSwiss generic drugmaker Sandoz filed a draft anti-dumping complaint with the European Commission over Chinese imports of the antibiotic ingredient amoxicillin.
Dr Bishal Gyawali explores why lowering the bar for drug approvals is a fallacy and why asking for better evidence is a sign of patient advocacy, not an attack on innovation.
Quantitative T2* MRI is feasible and reproducible for detecting microvasculopathy-related iron deposition in the soft tissues of the fingers.
An observational study suggests that bone mineral density may serve as a marker of systemic health.
Patients with autoimmune diseases who experience ocular inflammation while on adalimumab have an increased risk of developing antibodies against the drug, according to a recent retrospective study.
The World Health Organization has recommended prioritizing three experimental treatments for the Bundibugyo strain of Ebola.
Experts warn that concentrated herbal and dietary supplements are increasingly linked to severe liver injury, while regulation remains limited.
1.
Hereditary cancer has a rare and underreported cause.
2.
A consensus statement from researchers on the proper use of Lu-177 PSMA-617 radionuclide therapy and patient selection is published.
3.
After HSCT, a longer course of letermovir prophylaxis decreased the risk of cytomegalovirus infection.
4.
Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma
5.
Asymptomatic or Minimally Symptomatic Myelofibrosis
1.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
2.
Hope in Numbers: Understanding AML Leukemia Survival Rates and Emerging Therapies
3.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
4.
A Closer Look at the Effects of Sickle Cell on Eyesight
5.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge